Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: APVO
TL;DR
APVO filed an 8-K, standard update, no major news yet.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on September 16, 2024, reporting on other events and financial statements. The filing does not contain specific details on new events, financial figures, or material agreements within the provided text.
Why It Matters
This 8-K filing indicates that Aptevo Therapeutics Inc. is providing updates or disclosures to the SEC, which could be relevant for investors monitoring the company's regulatory compliance and corporate actions.
Risk Assessment
Risk Level: low — The filing is a routine 8-K and does not disclose any immediate material risks or significant negative events.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- September 16, 2024 (date) — Date of Report
- 206-838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What specific events are being reported in this 8-K filing by Aptevo Therapeutics Inc.?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as items being reported, but the provided text does not detail the specific nature of these events or statements.
What is the exact date of the earliest event reported in this 8-K?
The date of the earliest event reported is September 16, 2024.
What is the principal executive office address for Aptevo Therapeutics Inc.?
The principal executive offices are located at 2401 4th Avenue Suite 1050, Seattle, Washington, 98121.
What is the Commission File Number for Aptevo Therapeutics Inc.?
The Commission File Number for Aptevo Therapeutics Inc. is 001-37746.
What is the IRS Employer Identification Number for Aptevo Therapeutics Inc.?
The IRS Employer Identification Number for Aptevo Therapeutics Inc. is 81-1567056.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-09-16 08:09:44
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20240916.htm (8-K) — 38KB
- apvo-ex99_1.htm (EX-99.1) — 32KB
- img237228349_0.jpg (GRAPHIC) — 4KB
- 0000950170-24-106614.txt ( ) — 199KB
- apvo-20240916.xsd (EX-101.SCH) — 25KB
- apvo-20240916_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 16, 2024, Aptevo Therapeutics Inc. (the "Company") and Alligator Bioscience AB ("Alligator") issued a press release announcing data from the Phase 1 ALG.APV-527 monotherapy trial showing 60% of evaluable patients achieved stable disease in solid tumor study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. aptevo therapeutics inc. Date: September 16, 2024 By: /s/ Marvin L. White President and Chief Executive Officer